The results obtained in this study esablis that liposome formulations incorporating a synthetic polyethylene glycol-derivatied phospholipid have a pronounced effect on liposome tissue dt n and can produce a large increase in the pharmaologial eflkacy of encapsulated antitumor drugs. This effect is i ly greater than that observed previously with conventionl lposomes and is ith a more than 5-fold
blod, a marked decrease uptake by tissues such as liver ad spleen, and a corresponding increased accumulation i implanted tumors. These and other properties descrlbed here have expanded considerably the prospects of liposones as an effective carrier system for a variety of p active macromolecules.
Over the last 20 years, liposomes have served a dual role, as a valuable experimental tool for membrane research and in addition as an in vivo'delivery system for enhancing the efficacy of various pharmacologically active molecules (1) . Animal studies have shown that liposomes can decrease the toxicity of several antitumnor and antifungal drugs, leading to several recent clinical trials with promising results (2) (3) (4) (5) (6) . In addition, liposomes have been shown to be efficient carriers of antiparasitic drugs for treating intracellular infections of the reticuloendothelial system (RES), in activating macrophage cells to become tumoricidal in models of metastasis, and in enhancing the immune response to encapsulated antigens, thus facilitating the formulation of artificial vaccines (7, 8) . All these effects stem from the capacity of macrophage cells in the liver and spleen (mononuclear phagocytic system or RES) to remove the majority of liposomes from the blood circulation within minutes (9) . Such rapid clearance of conventional liposomes [i.e., liposomes composed of various phospholipids and cholesterol (Chol) and possibly other lipids, without specific components conferring the property of long circulation in blood] from the circulation, however, has limited their prospects as an in vivo delivery system for transporting drugs to sites of disease beyond the RES.
Recent reports from our laboratories have described liposome formulations (containing the monosialoganglioside GM1 or phosphatidylinositol) that exhibit a prolonged circulation time in blood ahd diminished uptake by the liver and spleen (10) (11) (12) and increased accumulation in implanted tumors (12) (13) (14) . The term "stealth" has been proposed (15) for-these long-circulating liposomes. We consider that such liposomes are sterically stabilized by the presence of the relevant headgroups on their surface (16) . In this report we present several findings obtained with liposomes sterically stabilized by the PEG headgroups of a synthetic phospholipid (PEG-DSPE) included in the formulation (PEG-liposomes). Preliminary experiments with PEG-liposomes have been published recently (17) (18) (19) . New microscopic evidence indicates that accumulation of liposomes in tumors involves extravasation, presumably due to increased permeability of the capillary endothelia (20, 21) . Unlike conventional liposomes, which show dose-dependent blood clearance kinetics (9, 22, 23) NaOI was obtained from the Edmonton Radiopharmaceutical Center; pyrogen-free saline for injection (0.9%6, USIP) was from Travenol Canada (Mississauga, ON). All test tubes, syringes, etc. were sterile and pyrogen-free. Desferalgallium-67 (67Ga-DF) was prepared as described (25) . Dextran labeled with rhodamine'B isothiocyanate (Rh-Dex; Mr 9000) was purchased from Sigma. Doxorubicin and epirubicin were obtained from Farmitalia, Carlo Erba (Milan). PEG (Mr -1900)-derivatized distearoyl phosphatidylethanolamine (PEG-DSPE) was synthesized as described (26 qTo whom reprint requests should be addressed.
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Liposome Preparation. Liposomes were prepared by thin film hydration as described (10, 12) . The resulting multilamellar vesicles at lipid concentrations of %10 ,.mol/ml were frozen (at -400C) and thawed (at 600C) several times and then passed repeatedly under pressure through 0.2-or 0.1-and 0.05-,um pore size polycarbonate membranes (27) , and the extrusion was repeated until the average size distribution was =80-100 nm in diameter (mean Gaussian distribution by volume). Liposome morphology was occasionally examined by electron microscopy (28, 29) .
For encapsulation of 67Ga-DF, the lippsomes were prepared with Desferal, and the 67Ga was loaded just before use (25) . lodinated tyraminylinulin was encapsulated as before (10) . Rh-Dex (Mr = 9000) was encapsulated passively by inclusion of the material at a concentration of 100 mg/ml in the preparation buffer. Free Rh-Dex was removed by gel permeation on a Sephadex G-150 column and an Amicon concentration unit with a Mr 30,000 cut-off filter. Liposomes containing doxorubicin or epirubicin were composed ofPEG-DSPE/HSPC/Chol/a-tocopherol (0.15:1.85:1.00:0.018, mol/mol) and were prepared as described (30) . The drug and total lipid concentrations of the final product were about 2 mg/ml and 20 gmol/ml, respectively (+10%o for both), and the particle diameter was 85 + 10 nm.
Animal Experimentation. Experiments with labeled inulin were performed in female ICR (outbred) mice (10) Mouse colon carcinoma (C-26) cells were injected into BALB/c female mice (6-9 weeks old) as before (31) . At day 0, mice were injected into the left flank s.c. with 4 x 105 cells in a volume of 0.1 ml. One day later drug was injected i.v. (tail vein, 0.2 ml or less, mouse weight between 16 and 21 g). Treatment was repeated at weekly intervals to a maximum of three injections. Tumor volume was measured as before (31) .
The lymphoma cell line J6456 was inoculated i.p. into BALB/c female mice (32) . When there was about 2 ml of ascitic fluid accumulated, containing between 108 and 109 tumor cells, the drug was injected i.v. either free in solution or in encapsulated form. The ascitic fluid was thereafter sampled at different intervals. Tumor cells were separated by centrifugation. Part of the supernatant was passed through a Dowex column to remove the non-liposome-associated drug (33) . The drug concentration was determined as before (30 We have also determined the blood clearance kinetics of several liposome formulations in rats by repeated sampling of blood, using 67Ga-labeled liposomes as above. Fig. 1 However, unlike sterically stabilized liposomes, they still show dose-dependent kinetics and saturation of liver uptake at high concentration (39) . W~hen a negatively charged phospholipid such as PG or phosphatidylserine was added to either of these two compositions, the uptake by the liver was much higher (12, 42) and that of the tumor much lower (12, 14) .
We have also examined the tumor tissue microscopically to determine whether the accumulated liposomes have extravasated beyond the endothelial barrier of the tumor vasculature. Rh-Dex was used as a water-soluble liposomeencapsulated marker to study the distribution of liposomes within the tumor mass by fluorescence microscopy. Fig. 3 shows a phase-contrast picture of a frozen section of tumor tissue, along with a picture of the same section observed in dark-field fluorescence microscopy. When a solution of nonencapsulated Rh-Dex was injected i.v., there was no detectable fluorescence in the tumor after 24 h. The photograph shown in Fig. 3 is representative of a large number of photographs taken from various sections of the tumor mass.
An uneven focal distribution of the fluorescence was observed within the tumor, with both dark areas and other highly fluorescent areas. Similar localization was observed by using a lipid fluorescent marker, rhodamine-labeled phosphatidylethanolamine, indicating that the fluorescence revealed by Rh-Dex in Fig. 3 probably represents intact liposomes. The fluorescence was localized well beyond the Proc. Nad. Acad Sci. USA 88 (1991) r I Proc. Natl. Acad. Sci. USA 88 (1991) 11463 heart, plasma, and ascitic fluid after i.v. injection of doxorubicin either free or encapsulated in PEG-liposomes. The ascitic fluid is an extravascular/extracellular fluid pool and is in direct contact with the tumor cells. The results indicate that encapsulation in PEG-liposomes diminished the early uptake of the drug by the heart and liver (lower values at 4 h) although the uptake in the liver was increased after 24 h, as observed earlier (12, 14) . Most importantly, there was a much higher concentration of the drug in plasma and in the ascitic fluid with the encapsulated formulation compared to the free drug. Separation offree drug on a Dowex column (30) showed that the majority of the drug present in the ascitic fluid was in intact liposomes and only 15-25% was free drug between 24 and 48 h. The concentration of the drug in the ascitic cells (mostly tumor cells) was initially lower but increased with time (Fig. 4) . These results, taken altogether, indicate that PEG-liposomes initially injected i.v. can extravasate into the peritoneal cavity where they provide a constantly high reservoir of encapsulated drug, available to be taken up by the tumor cells. Animals carrying no tumors did not accumulate any appreciable amount of liposomes into their peritoneal cavity, although liposomes are known to get transported from the peritoneal cavity to blood (11, 15) .
Anti-Tumor Efficacy of Drug-Containing Liposomes. Mouse colon carcinoma grown s.c. For the therapeutic experiments, multiple injections of liposomes composed of PEG-DSPE/HSPC/Chol loaded with epirubicin were given i.v. starting 1 day after s.c. inoculation of 4 x 105 C-26 tumor cells. The dosage of drug per injection was 6 and 12 mg/kg, and the initial injection was repeated twice (total of three injections) at 7-day intervals. The antitumor effects were registered by measuring tumor size and the survival of mice up to 120 days after tumor implantation. The results presented in Fig. 5 show clearly that encapsulation causes a marked improvement in therapeutic efficacy, inhibiting the tumor growth (Fig. 5A) long-term survivors (Fig. 5B) . The controls with injections of free drug or drug and empty liposomes showed only a slight prolongation of mean survival over untreated animals. Similar effects were obtained when liposomes were injected with a delay of 3 or 10 days, and the effect was smaller but still significant, even with a delay of 14 days (E.M., D.D.L., S. Babar, and F. J. Martin, unpublished work).
The doses of free and encapsulated drug were chosen on the basis of toxicity experiments performed in animals without tumors, with a similar regime of three doses at weekly intervals. These studies indicated that a dose of epirubicin at 9 mg/kg encapsulated in liposomes and at 6 mg/kg as free drug resulted in no deaths up to 120 days following injection. In the same period three deaths out of five animals were observed with epirubicin at 12 mg/kg encapsulated in liposome and at 9 mg/kg as free drug. On the basis of these results, we can conclude that the acute toxicity of epirubicin, as exemplified by the maximum tolerated dose, is reduced slightly following liposome encapsulation. As already shown in Fig. 5 , the therapeutic effect for a similar dose was increased markedly by liposome encapsulation. Thus, the therapeutic index of this drug (ratio of efficacy to toxicity) is considerably increased by encapsulation in PEG-liposomes. Earlier work had indicated that the C-26 colon carcinoma grown s.c. is not responsive to doxorubicin encapsulated into liposomes of conventional formulations (31) .
Mouse lymphoma grown i. (41, 44, 45) as well as their accumulation in tumors (14) depends on particle size in addition to specific lipids (10, 12) . Accumulation of small (-50-nm diameter) neutral liposomes (DSPC/Chol) in tumors had been observed earlier (46) . In our studies (12, 14) we have enhanced this accumulation by introducing liposome formulations with longer blood half-life and have increased their usefulness as a drug carrier by using liposomes of -100-nm diameter, which have a 16-fold higher internal volume as compared with smaller (50-nm) liposomes. We have recently proposed a mechanism for the prolonged blood clearance involving steric stabilization of the liposome surface (16) .
The high recovery in blood reported here with PEGliposomes and their accumulation in tumors (Fig. 3) (12) (13) (14) . The lower acute toxicity of anthracycline-loaded PEGliposomes reported here is similar to that observed earlier with conventional liposomes (47) (48) (49) (50) . It is probably related to the delayed clearance of drug from the blood and the reduction of peak plasma levels of free drug, which adversely affect sensitive tissues such as the heart and others involved in the acute toxic effects. Whether the increased therapeutic efficacy is due to the improved (delayed) blood clearance as seen recently with arabinose cytosine encapsulated in GMl-liposomes (51) or the increased local accumulation of drug within the tumor mass is not certain at present. It is possible that both factors contribute, although the latter is a more likely possibility.
The microscopic studies discussed above have indicated the presence of PEG-liposomes in the interstitial space around tumor cells. It is quite possible that their extravasation beyond the endothelial layer in tumors is the result of their long circulation time in blood and the increased permeability of the endothelial barrier in the newly vascularized tumors (12, 20, 21) . Although diffusion and deep penetration within the tumor mass is not expected for particles of the size of liposomes (20, 21) , it is possible that free drug can diffuse locally from the extravasated liposomes to the surrounding tumor cells. The presence of intact extracellular liposomes within the tumor area would provide a local depot for drug release. Enhanced localization of liposomes in other anatomically distinct regions might also be beneficial for other diseases involving areas of increased capillary permeability.
